Research programme: lysosomal channel 2 therapeutics - Autifony Therapeutics
Latest Information Update: 18 Oct 2022
Price :
$50 *
At a glance
- Originator Autifony Therapeutics
- Class Antidementias; Small molecules
- Mechanism of Action Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Lysosomal storage diseases; Parkinson's disease
Most Recent Events
- 06 Oct 2022 Early research in Lysosomal storage diseases in United Kingdom (Autifony Therapeutics pipeline, October 2022)
- 06 Oct 2022 Early research in Parkinson's disease in United Kingdom (Autifony Therapeutics pipeline, October 2022)